Bristol Myers Squibb
Public BMY · United States
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
12 approved
9 in Phase 3
Drugs
52
in active trials · 142 in all
Trials
145 active
552 since 2021
Drugs52
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Janus kinase inhibitor |
Approved | 18 Nov 2026soonPhase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 18 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Plaque Psoriasis, Psoriatic Arthritis and 9 more | ||||
| Open drug page | |||||
— |
Approved | 24 Nov 2026soonPhase 3 trial completes | |||
| Next date | 24 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Schizophrenia, Alzheimer Disease and 11 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 30 Nov 2026soonPhase 1/2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 30 Nov 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Multiple Myeloma | ||||
| Open drug page | |||||
CTLA-4 antibody |
Approved | 5 Feb 2027Phase 2 trial completes | |||
| How it works | A cancer drug that hits three targets | ||||
| Next date | 5 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Renal Cell Carcinoma, Solid Tumor and 16 more | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Approved | 5 Feb 2027Phase 2 trial completes | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 5 Feb 2027 · Phase 2 trial completes | ||||
| Also tested for | Melanoma, Advanced Solid Tumors and 31 more | ||||
| Open drug page | |||||
ROS1/TRK/ALK inhibitor |
Approved | 16 Feb 2027Phase 3 trial completes | |||
| Next date | 16 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Locally Advanced Solid Tumors, Metastatic Solid Tumors and 3 more | ||||
| Open drug page | |||||
Cardiac myosin inhibitor |
Approved | 13 Dec 2027Phase 4 trial completes | |||
| Next date | 13 Dec 2027 · Phase 4 trial completes | ||||
| Also tested for | Cardiomyopathy, Hypertrophic, Symptomatic Obstructive Hypertrophic Cardiomyopathy | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved | 31 Aug 2028Phase 1/2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 Aug 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Myelofibrosis | ||||
| Open drug page | |||||
BMS-986213not checked |
— |
On the market | 26 May 2029Phase 4 trial completes | ||
| Next date | 26 May 2029 · Phase 4 trial completes | ||||
| Also tested for | Melanoma, Cancer and 2 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 25 Aug 2029Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 25 Aug 2029 · Phase 2 trial completes | ||||
| Also tested for | Melanoma, Cancer and 1 more | ||||
| Open drug page | |||||
Receptor molecules, native or modified |
Approved | 30 Dec 2032Phase 3 trial completes | |||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Next date | 30 Dec 2032 · Phase 3 trial completes | ||||
| Also tested for | Renal Allograft Recipients | ||||
| Open drug page | |||||
Receptor molecules, native or modified |
Approved | — | |||
| How it works | A decoy protein that soaks up a signal molecule before it can reach the body's cells | ||||
| Also tested for | Rheumatoid Arthritis | ||||
| Open drug page | |||||
EGFR/HER3 bispecific antibody-drug conjugate |
Sichuan Baili (Biokin, SystImmune) |
Phase 3 | Nov 2026soonPhase 3 trial completes | ||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Solid Tumor and 44 more | ||||
| Open drug page | |||||
PD-L1/VEGF-A bispecific antibody |
BioNTech |
Phase 3 | 1 Jan 2027Phase 2 trial completes | ||
| How it works | A cancer drug that hits two targets at once | ||||
| Next date | 1 Jan 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, SCLC and 49 more | ||||
| Open drug page | |||||
— |
Phase 3 | 17 Aug 2027Phase 3 trial completes | |||
| Next date | 17 Aug 2027 · Phase 3 trial completes | ||||
| Also tested for | Extensive-Stage Small Cell Lung Cancer | ||||
| Open drug page | |||||
— |
Kardigan |
Phase 3 | Sep 2027Phase 2/3 trial completes | ||
| Next date | Sep 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Symptomatic Genetic Dilated Cardiomyopathy, Symptomatic Genetic Dilated Cardiomyopathy (DCM) | ||||
| Open drug page | |||||
— |
Phase 3 | 27 Dec 2027Phase 3 trial completes | |||
| Next date | 27 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis and 1 more | ||||
| Open drug page | |||||
Gene therapy substances |
Phase 3 | 30 Dec 2027Phase 3 trial completes | |||
| How it works | A gene therapy | ||||
| Next date | 30 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM) | ||||
| Open drug page | |||||
— |
Phase 3 | 17 May 2028Phase 2 trial completes | |||
| Next date | 17 May 2028 · Phase 2 trial completes | ||||
| Also tested for | Systemic Sclerosis, Systemic Lupus Erythematosus and 8 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | 15 Aug 2028Phase 2 trial completes | |||
| Next date | 15 Aug 2028 · Phase 2 trial completes | ||||
| Also tested for | Mesothelioma, Non Small Cell Lung Cancer and 10 more | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings33
Since Jan 2024 · All on SEC.gov- 29 OctReported quarterly results and made a public disclosure · SEC 8-K
- 30 JulReported quarterly results and made a public disclosure · SEC 8-K
- 8 MayFiled a report · SEC 8-K
- 30 AprReported quarterly results and made a public disclosure · SEC 8-K
- 5 FebReported quarterly results and made a public disclosure · SEC 8-K
- 12 JanMade a public disclosure · SEC 8-K
- 18 Nov 2025Reported other events · SEC 8-K
- 10 Nov 2025Reported other events · SEC 8-K
- 7 Nov 2025Offered new securities · 1 prospectus (424B5)
- 3 Nov 2025Offered new securities · 1 prospectus (424B2)
- 3 Nov 2025Reported other events · SEC 8-K
- 30 Oct 2025Reported quarterly results and made a public disclosure · SEC 8-K
- 31 Jul 2025Reported quarterly results and made a public disclosure · SEC 8-K
- 25 Jul 2025Changed a director or officer · SEC 8-K
- 7 May 2025Filed a report · SEC 8-K
- 24 Apr 2025Reported quarterly results and made a public disclosure · SEC 8-K
- 18 Feb 2025Changed a director or officer · SEC 8-K
- 6 Feb 2025Reported quarterly results and made a public disclosure · SEC 8-K
- 13 Jan 2025Made a public disclosure · SEC 8-K
- 31 Oct 2024Reported quarterly results and made a public disclosure · SEC 8-K
- 26 Jul 2024Reported quarterly results and made a public disclosure · SEC 8-K
- 18 Jun 2024Changed a director or officer · SEC 8-K
- 9 May 2024Filed a report · SEC 8-K
- 25 Apr 2024Reported quarterly results and made a public disclosure · SEC 8-K
- 18 Mar 2024Reported other events · SEC 8-K
- 18 Mar 2024Changed a director or officer · SEC 8-K
- 22 Feb 2024Reported other events · SEC 8-K
- 16 Feb 2024Offered new securities · 1 prospectus (424B5)
- 15 Feb 2024Changed a director or officer · SEC 8-K
- 14 Feb 2024Reported other events · SEC 8-K
- 13 Feb 2024Offered new securities · 1 prospectus (424B2)
- 2 Feb 2024Reported quarterly results and made a public disclosure · SEC 8-K
- 8 Jan 2024Made a public disclosure · SEC 8-K
About
- No active trial
- 90 other drugs
- Registry names
- 4 names in ClinicalTrials.gov Bristol-Myers Squibb
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Turning Point Therapeutics, Inc. - Sources
- ClinicalTrials.gov updated 16 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev